Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis

Yamamoto Wataru; Andou Taiki; Itabashi Megumi; Koyama Satoshi; Ishii Yoshimi; Numata Ayumi; Motohashi Kenji; Hagihara Maki; Matsumoto Kenji; Fujisawa Shin

首页> 外文期刊>Internal medicine. >Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis

【24h】

Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis

机译：Fludarabine / melphalan或Fludarabine / busulfan对血液系统恶性肿瘤患者进行调理方案后的同种异体造血干细胞移植：单中心分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective Fludarabine plus melphalan (FM) and fludarabine plus busulfan (FB) are two major conditioning regimens for allogeneic hematopoietic stem cell transplantation (allo-HSCT).

机译：目的氟达拉滨加美法仑（FM）和氟达拉滨加白消安（FB）是异基因造血干细胞移植（allo-HSCT）的两种主要条件。

著录项

来源
《Internal medicine.》 |2016年第13期|共7页
作者
Yamamoto Wataru; Andou Taiki; Itabashi Megumi; Koyama Satoshi; Ishii Yoshimi; Numata Ayumi; Motohashi Kenji; Hagihara Maki; Matsumoto Kenji; Fujisawa Shin;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内科学;
关键词
allogeneic stem cell transplantation; conditioning regimen; busulfan; melphalan;

机译：同种异体干细胞移植;治疗方案;白消安;美法仑;

相似文献

外文文献
中文文献
专利

1. Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis [J] . Yamamoto Wataru, Andou Taiki, Itabashi Megumi, Internal medicine. . 2016,第13期

机译：Fludarabine / melphalan或Fludarabine / busulfan对血液系统恶性肿瘤患者进行调理方案后的同种异体造血干细胞移植：单中心分析
2. Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine, and Total Body Irradiation Conditioning Is Effective in an Elderly and Infirm Population [J] . Brammer Jonathan E., Stentz Alexander, Gajewski James, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2015,第1期

机译：非白细胞异基因造血干细胞移植治疗白血球，氟达拉滨和全身照射条件的血液系统恶性肿瘤患者在老年人和体弱的人群中有效。
3. Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT [J] . Battipaglia Giorgia, Mauff Katya, Wendel Lotus, Bone marrow transplantation . 2021,第7期

机译：Thiotepa-Busulfan-Fludarabine（TBF）调理方案在接受同种异体造血细胞移植骨髓纤维化的患者中：EBMT慢性恶性工作组的结果分析
4. Fludarabine Phosphete and Melphalan - An Immunosuppressive Reduced Intensity Conditioning (RIC) Regimen for AUogeneic Stem Cell Transplantation in Patients with a Range of Hematological Malignancies [C] . G. Jackson, C. Richardson, G. Morgan, European Haematology Association . 2002

机译：Fludarabine phospete和Melphalan - 一种免疫抑制性降低的强度调理（RIC）治疗患者血液学恶性肿瘤患者的促孕酮干细胞移植方案
5. The burden of parainfluenza virus infection in patients with hematological malignancy and hematopoietic stem cell transplant (HSCT) recipients in the absence of active immunization and approved therapy: The role of infection control. [D] . Hanmod, Santosh S. 2009

机译：在没有积极免疫和批准治疗的情况下，血液恶性肿瘤和造血干细胞移植（HSCT）患者的副流感病毒感染负担：感染控制的作用。
6. Busulfan plus fludarabine compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematologic neoplasms: a meta-analysis [O] . Xiao-Ru Lei, Hong-Li Chen, Fang-Xia Wang, 2015

机译：血液肿瘤患者在造血干细胞移植前将白消安加氟达拉滨与白消安加环磷酰胺作为调理方案的比较：荟萃分析
7. CD34+ Cell Dose and Full Donor Chimerism at Day +100 Is Associated with Survival in Patients Who Received Reduced-Intensity Conditioning (RIC) With Fludarabine/Melphalan Prior To Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies [O] . Holtan S.G., Hogan W.J., Elliott M.A., 2009

机译：CD34 +细胞剂量和第100天的完全供体嵌合与在血液系统恶性肿瘤异基因造血干细胞移植（HSCT）之前接受氟达拉滨/美法仑降低强度调节（RIC）的患者的存活率相关

Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis

摘要

著录项

相似文献

相关主题

期刊订阅